Patient Preferences in Neoadjuvant Therapy for HER2+ Early-Stage Breast Cancer.

ABSTRACT: Purpose. Health technology assessment (HTA) focuses on overall survival (OS) as the key clinical endpoint when making oncology treatment decisions. However, capturing robust OS estimates in early-stage breast cancer (eBC) is challenging, and patients may value other endpoints. This study assessed patient preferences for treatment attributes and endpoints in neoadjuvant therapy where mature and nonconfounded OS is rarely available. Patients and Methods. An online discrete choice experiment (DCE) was developed with health care professionals and patient advisory groups and conducted in Germany, France, Italy, and Spain with patients with HER2+ eBC. Patients were presented with 15 tasks and in each asked to choose between 2 hypothetical treatment options or to opt out in the neoa

SUBMITTER: Batchelder L 

PROVIDER: S-EPMC12501434 | biostudies-literature | 2025 Jul-Dec

REPOSITORIES: biostudies-literature